Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Jul 27 - Aug 1
While both exhibit unique mechanisms and promising applications, their contrasting amino acid structures and functions cater to specific needs
The first principle is that an antibody-dependent effect in vitro does not represent or predict ADE of disease without proof of a role for the antibody in the pathogenesis of a more severe clinical outcome
Investment opportunities made under CF come in various structures
TB-500 (Thymosin Beta-4) Evidence level : Clinical trials in progress, strong preclinical evidence Key studies : Study 1: Wound healing (Philp et al., 2003) Enhanced keratinocyte migration Faster wound closure Improved healing quality Study 2: Cardiac repair (Bock-Marquette et al., 2004) Promoted cardiac cell survival post-infarction Enhanced angiogenesis Improved heart function Study 3: Muscle regeneration (Spurney et al., 2010) Muscular dystrophy model Improved muscle function Reduced inflammation Clinical trials : Phase 2 trials for cardiac conditions Phase 3 trials for ophthalmology Ongoing research for various applications Mechanism confirmed : Promotes cell migration, reduces inflammation, enhances tissue remodeling
US$ 21.35
US$ 21.71
US$ 21.40
US$ 25.82
US$ 24.54
US$ 28.06